CanG
CanG · page 3
- Medical
German Doctors Can Now Prescribe Reimbursed Medical Cannabis Without Prior Approval, But Cannabis Sentiment Wanes
From October 17, the majority of doctors in Germany will be able to prescribe medical cannabis for reimbursement without securing prior approval of the health insurance companies.
- Data & Analysis
German Medical Cannabis Market to Top €420m in 2024 Amid ‘Second Wave of German Cannabis’
Germany’s flourishing medical cannabis market is now forecast to top €420m this year, according to Prohibition Partners’ upcoming German Cannabis Report.
- Adult-Use
Where Are Germany’s Planned Cannabis Model Projects?
Germany’s long-anticipated ‘Pillar 2’ is in danger of being abandoned by the government amid ongoing political roadblocks both domestically and from the EU.
- Hemp Industry
Germany Moves to Overturn Controversial Hemp Law but Legal Prosecutions Continue
In July, Germany submitted a draft of its Industrial Hemp Liberalization Act, a bill that promises to do away with the baffling and controversial ‘intoxication clause’.
- Medical
Calls to Restrict Medical Cannabis Prescriptions in Germany Grow as the Flourishing Market Shows No Signs of Slowing Down
Medical cannabis prescriptions have exploded across Germany since April 01 when its landmark CanG Act was brought into force.
- Markets & Stocks
Chill Brands Ousted Directors Transferred $400k to Personal Accounts While CEO Absent, & Germany’s CanG Changes Boost Cannovum’s Stock
Chill Brands [stock_market_widget type=”chart” template=”line” assets=”CHLL.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Chill Brands’ ongoing boardroom debacle took another dramatic turn this week following revelations that its ousted directors acted ‘to defraud the business’ while its CEO was temporarily suspended.
- Press releases
Bloomwell Group Unites Brands and Operations to Form Germany’s Largest Digital Platform for Medical Cannabis
Award-winning Frankfurt-based company Bloomwell Group GmbH (“Bloomwell Group”) today announced the launch of Germany’s largest centralised digital platform for medical cannabis with regards to participating users, creating a one-stop shop for patients, physicians, pharmacies and suppliers all under the Bloomwell brand name.
- Policy & Regulation
Cannabis Regulation and THC Driving Limits Under Scrutiny in Bundestag Hearings
On Monday, 4th June 2024, two expert hearings were held regarding the laws ‘to amend the Cannabis Consumption Act and the Medical Cannabis Act’ and the ‘Sixth Law to Amend the Road Traffic Act and Other Road Traffic Regulations’.
- Policy & Regulation
New Cannabis Regulations in Bundestag: Traffic Rules, Cultivation Restrictions, and Training Programs
Written for Business of Cannabis by Prohibition Partners Senior Analyst Alex Khourdaji In the late evening of 16th May 2024, the Bundestag held its first reading of the first draft law to amend the Consumer Cannabis Act and the Medical Cannabis Act in the Bundestag as well as amendments to the Road Traffic Act.
- Data & Analysis
Proposed Amendments to the Cannabis Act (CanG) Considered Unconstitutional
A series of proposed amendments to the Cannabis Act (CanG) which would further constrain cultivation associations could be brought in before July 1st. According to a neutral assessment from law firm Witzel Erb Backu & Partner, these amendments may be in violation of the German constitution.
- Adult-Use
Germany’s ‘Pillar 2’ Is Already Being Worked On and Could Be Here Far Sooner Than Expected
Germany’s highly anticipated ‘Pillar 2’, which would seek to implement a Switzerland-style adult-use cannabis pilot project model, is now being worked on by the German government.
- Policy & Regulation
Cannabis Associations in Germany Face New Restrictions in Push to Prevent Commercialisation
The German government is reportedly set to push through legislation that would tighten the already strict rules around cultivation associations.
